Khanna Rahul, Bhadani Shilpi, Khanna Seema, Pandey Manoj, Kumar Mohan
Indian J Surg. 2011 Apr;73(2):107-10. doi: 10.1007/s12262-010-0181-6. Epub 2010 Nov 16.
The best method of pathological evaluation of sentinel lymph node in breast cancer has not been agreed upon. Immunohistochemical (IHC) techniques have shown a greater sensitivity over conventional histology for the detection of micrometastais. The aim of the study was to determine whether IHC for Epithelial Membrane Antigen (EMA) on the sentinel node could be more sensitive than conventional histology for diagnosing micrometastasis in sentinel lymph nodes. Eighty-four clinically node negative breast cancer patients underwent sentinel node biopsy at time of surgery for breast cancer. The node was subjected to conventional histopathology as well as IHC for EMA. The sensitivity of histology viz a viz IHC for EMA for detection of sentinel node metastasis was 88% and the specitficity was 96%. The overall diagnostic accuray of histology viz a viz IHC was 93%. There were 4 patients with micrometastasis (<2.0 mm), which were positive on IHC but negative on histology. Two patients with poorly differentiated breast cancer had a false negative IHC for EMA result as compared to histology. Immunohistochemistry for Epithelial Membrane Antigen can increase the detection rate of micrometastasis in sentinel lymph node. This can have important bearing on deciding the need of adjuvant systemic therapy. A false negative result for EMA may be seen in patients with poorly differential cancer. Therefore the best policy seems to employ both histopathology and IHC for EMA for the comprehensive evaluation of sentinel lymph node in breast cancer.
乳腺癌前哨淋巴结病理评估的最佳方法尚未达成共识。免疫组织化学(IHC)技术在检测微转移方面比传统组织学表现出更高的敏感性。本研究的目的是确定前哨淋巴结上皮膜抗原(EMA)免疫组织化学检测在诊断前哨淋巴结微转移方面是否比传统组织学更敏感。84例临床腋窝淋巴结阴性的乳腺癌患者在乳腺癌手术时接受了前哨淋巴结活检。对该淋巴结进行了传统组织病理学检查以及EMA免疫组织化学检测。组织学与EMA免疫组织化学检测前哨淋巴结转移的敏感性为88%,特异性为96%。组织学与免疫组织化学的总体诊断准确率为93%。有4例微转移(<2.0mm)患者,免疫组织化学检测为阳性,但组织学检查为阴性。与组织学相比,2例低分化乳腺癌患者的EMA免疫组织化学检测结果为假阴性。上皮膜抗原免疫组织化学检测可提高前哨淋巴结微转移的检出率。这对于决定辅助全身治疗的必要性可能具有重要意义。在低分化癌患者中可能会出现EMA假阴性结果。因此,最佳策略似乎是同时采用组织病理学和EMA免疫组织化学检测来综合评估乳腺癌前哨淋巴结。